

> ISCHEMIC STROKE


# STROKE

ISCHEMIC STROKE

原因

• Embolic: artery → artery, cardioembolic (~30% due to AF; _NEJM_ 2014;370:2478), paradoxical

• Thrombotic: large vessel (atherosclerosis) vs. small vessel (“lacunar,” lipohyalinosis of small arteries, often related to smoking, HTN, hyperlipidemia, & DM)

• Other: dissection, vasculitis, vasospasm, hypercoag, hypoperfusion, endocarditis, venous

臨床表現

• Timing: embolic → sudden onset; thrombotic → may have stuttering course

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p>Stroke Syndromes by Vascular Territory</p></td></tr><tr><td><p>Artery</p></td><td><p>Deficits</p></td></tr><tr><td><p>ICA → Ophth</p></td><td><p>Amaurosis fugax (transient monocular blindness)</p></td></tr><tr><td><p>ACA</p></td><td><p>Hemiplegia (leg &gt; arm), abulia, urinary incontinence, primitive reflexes</p></td></tr><tr><td><p>MCA</p></td><td><p>Hemiplegia (face &amp; arm &gt; leg); hemianesthesia; homonymous hemianopia</p><p>Aphasia if dom. hemisphere: sup. div. → expressive; inf. div → receptive</p><p>Apraxia &amp; neglect if nondom. hemisphere.</p></td></tr><tr><td><p>PCA</p></td><td><p>Macular-sparing homonymous hemianopia; alexia without agraphia</p><p>Thalamic syndromes with contralateral hemisensory disturbance</p></td></tr><tr><td><p>Vertebral, PICA</p></td><td><p>Wallenberg syndrome = numbness of ipsilateral face and contralateral limbs, diplopia, dysarthria, dysphagia, ipsilateral Horner’s, hiccups</p></td></tr><tr><td><p>Basilar</p></td><td><p>Pupillary Δs (midbrain=dilated, pons=pinpoint), long tract signs (quadriplegia, sensory loss), CN 異常, cerebellar dysfxn. Top of basilar → “locked in” synd.</p></td></tr><tr><td><p>Cerebellar</p></td><td><p>Vertigo, N/V, diplopia, dysarthria, nystagmus, ipsilateral limb ataxia</p></td></tr><tr><td><p>Lacunar (arterioles)</p></td><td><p>5 major syndromes: pure hemiplegia, pure hemianesthesia, ataxic hemiparesis, dysarthria + clumsy hand, mixed sensorimotor</p></td></tr></tbody></table>

Transient ischemic attack (TIA)

• Sudden deficit due to cerebral ischemia; **no stroke on imaging;** most resolve in <1 h

• Ddx: seizure, migraine, hypoglycemia, amyloid spells, TGA, anxiety

• Risk of subsequent stroke ~2% by 1 wk (_NEJM_ 2016;374:1533). Can stratify based on **ABCD2: A**ge ≥60 y (+1); **B**P ≥140/90 (+1); **C**lin features: unilat. weak. (+2), speech impair. without weakness (+1); **D**uration ≥60 (+2) or 10–59 min (+1); **D**M (+1)

Physical exam

• General: murmurs, carotid & subclavian bruits, peripheral emboli, endocarditis stigmata

• Neurologic exam, NIH stroke scale ([http://www.ninds.nih.gov/doctors/NIH\_Stroke\_Scale.pdf](http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf))

Acute workup

• Electrolytes, Cr (relevant for contrast); glc, CBC, coags (see exclusion criteria for lysis)

• Cardiac biomarkers, 12-lead ECG, tox screen

• **STAT CT** to 排除 ICH prior to lysis. (Se ICH ≈ MRI, CT faster). Early signs of stroke: hyperdense artery, loss of gray-white differentiation, edema, insular ribbon. CT can be 正常 initially, and not Se for small & brainstem. CTA if considering endovascular intervention.

Acute 治療 of ischemic stroke (_Lancet_ 2017;389:641; _Stroke_ 2018;49:e46)

• **Thrombolysis (IV):** tPA 0.9 mg/kg (max 90 mg), with 10% as bolus over 1 min, rest over 1 h

consider if onset within 4.5 h, ∅ ICH, ∅ contraindic. (incl. current/prior ICH; head trauma or stroke within 3 mo; intracranial neoplasm, AVM or aneurysm; recent intracranial/intraspinal surgery; active internal bleeding; noncompressible arterial puncture; ↑ BP; multilobar infarct; plt <100k, INR >1.7, on Xa inhib, PTT >40, glc <50)

0–3 h: 12% absolute ↑ in good neuro outcome (min/no disability), 5.8% absolute ↑ in ICH, trend toward 4% absolute ↓ mortality

3–4.5 h: 7.4% absolute ↑ in good neuro outcome, 1.8% absolute ↑ in ICH, ∅ mortality benefit (nb, trial excluded patients with previous strokes + DM)

Data for TNK, Rx up to 9 h, and for MRI imaging to guide Rx (_NEJM_ 2018;378:1573 & 379:611; 2019;380:1795)

• BP: lower to <185/110 to consider lysis; if lyse keep <180/105 × 24 h (consider labetalol or nicardipine), otherwise permissive HTN unless >220/120 or sx; if sx HoTN consider vasopressors

• Initiate ASA within 24–48 h; avoid anticoagulation within 24 h of lysis; see below for long-term Rx

• Cerebral edema → herniation: 1–5 d post large MCA or cerebellar strokes, ↑ risk in young. Elevate HOB >30°; mannitol ± 23% NaCl. Hemicraniectomy ↓ mortality (_NEJM_ 2014;370:1091). Neurosurgery consult in select MCA and all large cerebellar strokes.

• **Endovascular thrombectomy** indicated if within 6 h of sx onset, pre mRS 0-1, occlusion in ICA or MCA, NIHSS ≥6 (臨床severity), ASPECTS ≥6 (CT based likelihood of recovery) (_NEJM_ 2015;372:11, 1009, 1019, 2285 & 2296; _Lancet_ 2016;387:1723). May extend to 6–24 h if mismatch between infarct size and 臨床deficits or stroke penumbra (_NEJM_ 2018;378:11 & 708).

### Workup to assess for etiology/modifiable risk factors

• Cardiac: prolonged Holter for AF (eg, 10 d at presentation, 3 & 6 mo detects in 14%); TTE to 排除 thrombus/veg, with bubble study to 排除 PFO/atrial septal aneurysm if suspect embolic

• Vessel imaging: CTA or MRA head/neck; carotid U/S with Doppler if contraindic to CTA/MRA

• Labs: lipids, HbA1c, TSH, homocysteine, Lp(a), hypercoag workup (if <65 y or cryptogenic stroke; ideally drawn before starting anticoag), ESR/CRP, blood cx if signs and symptoms systemic infection

• **MRI** helpful if dx of stroke unclear (esp. post circ) or to define stroke subtype, age, exact size

_DWI_ bright/_ADC_ dark = earliest finding in acute ischemia (~w/in mins, up to days)

_T2-FLAIR:_ hyperintense within hrs, persists for wks; _PWI_ differentiates irreversibly infarcted core vs. viable penumbra; _T1 fat-sat_ (neck vessels) if suspicious for dissection

Secondary stroke prevention (_NEJM_ 2012;366:1914)

• **Antiplatelet therapy:** different agents likely have similar efficacy

### ASA ↓ death & repeat stroke; equal to warfarin in nonembolic stroke (_NEJM_ 2001;345:1444)

**clopidogrel:** marginally superior to ASA, slightly ↑ ICH (_Lancet_ 1996;348:1329)

### clopidogrel + ASA (vs. ASA alone): Rx for 21 d in minor strokes/TIA → ↓ risk of stroke, ? ↑ ICH; longer Rx not better & ↑ ICH (_NEJM_ 2013;369:11 & 2018;379:215; _BMJ_ 2018;363:k5108) Rx for 90 d if stroke due to intracranial athero (_NEJM_ 2011;365:993)

• **Anticoagulation (AC):** consider for AF (qv), cardiac/paradoxical emboli (except bacterial endocard); large extra-dural dissections; hypercoag; bridge to CEA in sx carotid stenosis

### Hold off on AC in large strokes for ~2–4 wk given risk of hemorrhagic conversion

• Long-term SBP target 120–139 mmHg (_JAMA_ 2011;306:2137)

• ↓ LDL-C (<< 70 mg/dL): ↓ recurrence with statin PCSk9i added to statin (_NEJM_ 2017;376:1713)

• Fluoxetine: improved motor recovery after 3 mo (_Lancet Neurol_ 2011;10:123)

• **Carotid revascularization** (_NEJM_ 2013;369:1143)

### CEA (_if_ surgical morbidity & mortality ≤6%) indicated for:

_sx stenosis_ 70–99% (benefit ↑ for males, >75 y, ≤2 wk from stroke) → 65% ↓ RR of repeat stroke, slight benefit for 50–69% stenosis (_NEJM_ 1991;325:445; _Lancet_ 2004;363:915)

_asx stenosis_ 70–90%, <79 y: 50% ↓ RR of repeat stroke (_Lancet_ 2010;376:1074)

**Stenting:** c/w CEA, periprocedural stroke ↑ (esp. in elderly) & MI ↓ (but many asx), subseq. stroke rate ≈ (_NEJM_ 2016;374:1011 & 1021; _Lancet_ 2016;387:1305; _Lancet Neuro_ 2019;18:348)

Patent foramen ovale (PFO; in ~27% of population) (_NEJM_ 2005;353:2361)

• ↑ stroke risk: ≥4 mm separation, R→L shunting at rest, ↑ septal mobility, atrial septal aneurysm

• If PFO & stroke/TIA: no benefit of warfarin over ASA (_Circ_ 2002;105:2625), but consider if at high risk for or has DVT/PE. Closure ↓ recurrence by ≥50% if ↑ risk features (see above) and absence of factors suggesting alternate etiology (_NEJM_ 2017;377:1011, 1022, 1033). **RoPE score:** age (+1 for each decade <70); cortical stroke on imaging (+1); HTN, DM, h/o stroke/TIA, smoker (+1 for each _absent_ risk factor). Consider closure if >7 (_JAHA_ 2018;7:1).

INTRACRANIAL HEMORRHAGE (ICH)

Classification by location

• Hemorrhagic strokes: intraparenchymal hemorrhage (IPH) & subarachnoid hemorrhage (SAH)

• Other ICH: epidural hematoma (EDH) & subdural hematoma (SDH)

原因

• AVM, aneurysm, cerebral venous sinus thrombosis → IPH or SAH

• HTN (basal ganglia, cerebellum, brainstem), cerebral amyloid (lobar), tumor (esp. with melanoma, renal cell CA, chorio-CA, thyroid CA) → IPH

• Trauma → all locations (nb, IPH or SAH caused by trauma technically not a stroke)

臨床表現 (_Lancet_ 2017;389:655 & _NEJM_ 2017;377:257)

• ↓ consciousness, N/V, HA, progressive focal neurologic deficits

• _SAH:_ thunderclap HA, onset with exertion; nuchal pain/rigidity; LOC. _EDH:_ initial lucid interval.

Workup (_Acad Emerg Med_ 2016;23:963)

• STAT CT brain, angio (CT-A or conventional) if suspicious for vascular source

• ? LP for xanthochromia if no evid of ICH on CT (although ⊖ LR 0.01) & suspicious for SAH

• Coags (PT, PTT, INR)

Management (_Crit Care Med_ 2016;44:2251; _JAMA_ 2019;321:1295)

• Reverse coagulopathy, INR <1.4. Plt >100k, no need for plt tx if on antiplt Rx (? if ↑ ICH), DDAVP if uremic. 2-3 mo after recovers, can restart antiplt mono Rx (_Lancet_ 2019;393:2013).

• BP control with art line, nicardipine or labetalol gtt. SBP goal <140 for 1st 24 h, then <160 (_NEJM_ 2013;368:2355 & 2016;375:1033), though BP goals controversial (_NEJM_ 2016;375:1033)

• SAH: endovasc coiling vs. surg clipping (depends on location, comorbid.; _Lancet_ 2015;385:691) of aneurysm/AVM; nimodipine to ↓ risk of vasospasm (monitor with TCDs), seizure Ppx

• Surg evac: EDH; SDH if >1 cm or rapid ↑; IPH: no obvious benefit (_Lancet_ 2013;382:397)

• Venous sinus thrombosis: start anticoagulation, manage ↑ ICP and seizures as needed
